India’s proposed easier drug rules could help pharma companies shorten development timelines, accelerate generic launches, and improve access to affordable medicines.
GSK’s oncology buying spree gains momentum with a USD 750 million blood cancer bet targeting a potential new multiple myeloma treatment.
Lilly claims 30 percent share as the oral weight-loss race intensifies, challenging Novo Nordisk’s early lead in the growing obesity treatment market.
AI-backed cancer care gains international attention as India-built iOncology.ai earns recognition at BRICS while moving toward clinical validation.
Pharma’s rough patch deepens as fines, clinical failures and market fallout put safety, efficacy and investor confidence under pressure.
India’s biopharma sector is gaining regulatory strength as Biopharma SHAKTI and IPC’s quality push support biologics and biosimilars growth.
USFDA inspections across three Indian-linked pharma facilities reveal varied compliance outcomes, from minimal observations to Form 483 and VAI classification.
MSD has inaugurated a technology centre in Hyderabad, strengthening its global technology network and supporting Human Health through digital and enterprise capabilities.
India’s race to eliminate cervical cancer gains momentum as HPV vaccination crosses 80 lakh doses, strengthening the country’s prevention efforts.
Alembic’s Vadodara facility completes a major compliance turnaround, moving from a warning letter to a zero-observation USFDA inspection.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")